ResearchAssessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
ResearchThe impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
ResearchResponse and outcomes of patients with mutated accelerated/blast-phase myeloproliferative neoplasms
ResearchCAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
ResearchNo clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
ResearchIntensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
ResearchImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
ResearchIncidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation
ResearchOutcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL